A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of GLPG3667 in Adult, Healthy Male Subjects
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Gent, Belgien, 9000
- Drug Research Unit Ghent
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male between 18 and 55 years of age (extremes included), on the date of signing the informed consent form (ICF).
- A body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.
- Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and fasting clinical laboratory safety tests, available at screening and prior to randomization. Hemoglobin, neutrophil, lymphocyte, and platelet counts must be above the lower limit of normal range. Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be below the upper limit of normal. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator.
This list only contains the key inclusion criteria.
Exclusion Criteria:
- Known hypersensitivity to investigational product (IP) ingredients or history of a significant allergic reaction to IP ingredients as determined by the investigator.
- Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A that has resolved at least 3 months prior to first dosing of the IP.
This list only contains the key exclusion criteria.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: GLPG3667 SD
Participants will receive a single dose of GLPG3667
|
GLPG3667 kapsler
|
|
Placebo komparator: Placebo SD
Participants will receive a single dose of matching placebo
|
Matchende placebo kapsler
|
|
Eksperimentel: GLPG3667 MD
Participants will receive repeated doses of GLPG3667 for 13 days.
|
GLPG3667 kapsler
|
|
Placebo komparator: Placebo MD
Participants will receive repeated doses of matching placebo for 13 days.
|
Matchende placebo kapsler
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations
Tidsramme: From screening through study completion, an average of 3 months
|
To evaluate the safety and tolerability of single and multiple oral doses of GLPG3667, in adult, healthy, male subjects compared with placebo
|
From screening through study completion, an average of 3 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of GLPG3667 - SD
Tidsramme: Between Day 1 pre-dose and Day 4
|
To evaluate the PK of single and multiple oral doses of GLPG3667 in adult, healthy male subjects.
|
Between Day 1 pre-dose and Day 4
|
|
Maximum observed plasma concentration (Cmax) of GLPG3667 - MD
Tidsramme: Between Day 1 pre-dose and Day 16
|
To evaluate the PK of single and multiple oral doses of GLPG3667 in adult, healthy male subjects.
|
Between Day 1 pre-dose and Day 16
|
|
Area under the plasma concentration-time curve (AUC) of GLPG3667 - SD
Tidsramme: Between Day 1 pre-dose and Day 4
|
To evaluate the PK of single and multiple oral doses of GLPG3667 in adult, healthy male subjects.
|
Between Day 1 pre-dose and Day 4
|
|
Area under the plasma concentration-time curve (AUC) of GLPG3667 - MD
Tidsramme: Between Day 1 pre-dose and Day 16
|
To evaluate the PK of single and multiple oral doses of GLPG3667 in adult, healthy male subjects.
|
Between Day 1 pre-dose and Day 16
|
|
Terminal elimination half-life (t1/2) of GLPG3667 - SD
Tidsramme: Between Day 1 pre-dose and Day 4
|
To evaluate the PK of single and multiple oral doses of GLPG3667 in adult, healthy male subjects.
|
Between Day 1 pre-dose and Day 4
|
|
Terminal elimination half-life (t1/2) of GLPG3667 - MD
Tidsramme: Between Day 1 pre-dose and Day 16
|
To evaluate the PK of single and multiple oral doses of GLPG3667 in adult, healthy male subjects.
|
Between Day 1 pre-dose and Day 16
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Natalia Rueda-Rincon, MD, PhD, Galapagos NV
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GLPG3667-CL-118
- 2021-002488-23 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .